Pharvaris is a biopharmaceutical company developing treatments for rare disorders involving abnormal bradykinin activity, particularly angioedema conditions. The company's lead candidate, deucrictibant, is a small molecule drug in phase 3 testing that blocks bradykinin B2 receptors to treat acute attacks and provide ongoing prevention in hereditary angioedema and acquired angioedema linked to C1-inhibitor deficiency, with multiple formulations in development. Founded in 2015 and based in Switzerland, the company addresses therapeutic gaps in bradykinin-mediated disease management.

entry readiness 12 · NOT READY · exit proximity 0

Value area 31.73–39.20 · 66% of 120d volume overhead · heavy supply